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We present a method to detect the transporter activity of intact adherent cells using a
microchamber device. When adherent cells are seeded onto the poly-di-methyl siloxane
substrate having microchambers with openings smaller than the size of a cell, the cells
form a confluent layer that covers the microchambers, creating minute, confined spaces.
As substances exported across the cell membrane accumulate, transporter activity can
be detected by observing the fluorescence intensity increase in the microchamber. We
tested the microchamber device with HeLa cells over-expressing MDR1, an ATP-binding
cassette transporter, and succeeded in detecting the transport of fluorescence-conjugated
paclitaxel, the anti-cancer drug, at the single-cell level.
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INTRODUCTION
Cells take up and release various substances across the cellular
membrane. The underlying mechanisms include passive diffusion,
substance-specific passive or active transport via membrane pro-
teins, and endo- and exocytosis through vesicles. Through these
mechanisms a variety of substances are transported, such as fat-
soluble to aqueous-soluble substances and small molecules to
large substances. Because membrane transport plays a key role
in various physiological activities, the development of methods
to measure the transport of such substances is expected to have a
wide range of applications, from basic biological sciences to clinical
applications.
Among membrane proteins that transport physiologically
active substances (e.g., glucose, amino acids) between the exterior
and interior of cells are the transporter proteins. Since transporters
are also involved in the efflux of drugs, they have an impact
on pharmacokinetics. Above all, the efflux of anti-cancer drugs
by ATP-binding cassette (ABC) transporters expressed on cancer
cells is of particular importance (Leonard et al., 2003; Szakacs
et al., 2006; Huang, 2007; Mellor and Callaghan, 2008). This drug
transporter induces multi-drug resistance, which shows resistance
against anti-cancer drugs with many different structures or mecha-
nisms of action in cancer cells. Thus, ABC transport is considered
to be the major factor in cases where the drug is not effective.
ABC transporters export substances by using energy derived from
ATP hydrolysis (Klein et al., 1999). Among various subfamilies,
MDR1/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 are primarily
involved in anti-cancer resistance (Gottesman et al., 2002). A trans-
porter encoded in theMDR1/ABCB1 gene is called P-glycoprotein,
which is expressed in normal cells such as those in the kidneys and
adrenal glands, and plays a role in biological defense by exporting
toxic substances. When P-glycoprotein is over-expressed in cancer
cells, anti-cancer drugs will be exported to the outside of the cells
and the intracellular accumulation of the drug decreases, leading
to the acquisition of resistance by the cancer cells. MDR1 has a
wide range of substrate specificities and is involved in resistance
against diverse chemical structures, including anthracyclines,
vinca alkaloids, and taxanes (Thomas and Coley, 2003).
Several analytical methods are available to quantify the trans-
port activity of either transporter-expressing cells or vesicles with
reconstituted transporters (e.g., scintillation counter, fluorescent
plate reader, flow cytometry) (Aszalos, 2007; Giacomini et al.,
2010). However, these methods are endpoint assays and transport
dynamics cannot be resolved. To directly quantify the transport
of substrates across the cellular membrane, the transwell device
is widely used. In this device, a confluent monolayer of cells
with tight occluding junctions (e.g., Caco-2, MDCK, LLC-PK1) is
prepared over a membrane with micrometric holes. As the trans-
porters are expressed only on the apical side, directional transport
of substrates across the cell layer can be measured. These meth-
ods are used widely to screen drugs against certain transporters.
However, these methods only provide the average behavior of a cel-
lular population. It has been widely recognized that, among cells
derived from the same tissue, there are wide genetic and functional
varieties (Michor and Polyak, 2010; Visvader, 2011; Renovanz and
Kim, 2014). The heterogeneity in cancer cells, especially, may affect
drug efficacy and reduce the quality of treatment. Therefore, a sim-
ple device that can measure the transport activity of cells at the
single-cell level would be beneficial to analyze clinical samples.
Moreover, such a device could be expected to reduce the amount
of cells that need to be analyzed, alleviating the burden on patients.
With the advance of micro total analysis system technology
(µTAS), various microdevices for singe-cell and single-molecule
analysis are becoming available, not only for fundamental biology
but also for clinical diagnostics (Sims and Allbritton, 2007; Kovarik
et al., 2012; Culbertson et al., 2014). Several devices that measure
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the activity of transporters have been reported so far. Unlike ion
channels, whose activity can be measured electrically, substrates of
transporters are various and often have no charge. For this reason,
detection of metabolites exported via transporters is principally
dependent on fluorescence, which is monitored using fluorescence
microscopes. When transported substrates accumulate in a small,
closed space, high concentrations can be achieved within a short
period of time, leading to highly sensitive detection.
Measurement of the transport activity of non-adherent cells
at a single-cell level can be realized by trapping cells within a
microchamber or microfluidics device and directly observing the
translocation of fluorescent substrate. Iino et al. (2012) reported a
screening method for drug resistant bacteria: Escherichia coli was
trapped together with fluorogenic substrates within a femtoliter
chamber or droplet array and the localization of fluorescent sub-
strates degraded by β-galactosidase was examined. In addition, Li
et al. (2008, 2011) reported a method to monitor the efflux and
accumulation of fluorescent anti-cancer drugs for a single cell from
the leukemic (CEM) cell line, trapped by a retention structure on
a microfluidic chip.
Moreover, the measurement of membrane transport at a single
transporter molecule level has been attempted. Tschodrich-Rotter
and Peters (1998) attached the membranes of erythrocytes onto
an isoporous polycarbonate filter, and the passive transport of
fluorescent protein B-phycoerythrin through pores created by
streptolysin O was detected. Kiskin et al. (2003) used a simi-
lar method to measure passive transport of nuclear transport
receptor NTF2 and its homolog NXT1 through pores in nuclear
membranes of Xenopus oocytes using a microchamber (Kiskin
et al., 2003; Peters, 2003). Furthermore, several groups have suc-
ceeded in detecting the activity of single transporters embedded
in artificial, reconstituted membranes that cover a microchamber
(Hemmler et al., 2005; Barriga et al., 2014; Watanabe et al., 2014).
In these pilot experiments, the performance of microdevices in
detecting passive transport was primarily tested, due to the ease
of experiment, although they expect the same strategy will enable
the measurement of active transport.
In the pharmacotherapy of cancer, there is wide variation
among individuals in treatment efficacy and the development
of side effects from anti-cancer drugs, due to the acquisition of
resistance by cancer cells as well as polymorphisms in patients.
A clinical diagnostic device that detects the activity of trans-
porters based on cells collected from cancer patient biopsies could
help predict the efficacy and side effects of certain drugs, and
contribute to the selection of appropriate anti-cancer treatments
for individual patients. As seen in the above examples, trans-
port of substances via membrane transporters can be detected
rapidly and easily at the single-cell or single-molecule level using
microdevices. As solid tumors account for most tumors that
consist of adherent cells, a microdevice that measures trans-
port activity of adherent cells under near-physiological conditions
is of particular importance. Thus, in this study, we develop a
microchamber device for the detection of transport activity, in
which drugs, as substrates, are exported from cells and accumu-
late within a confined space of the microchamber directly covered
by adherent, cultured cells (Figure 1). Here, cultured cells over-
expressing MDR1 proteins were used to test the performance of
FIGURE 1 | Schematic of the microchamber system for detection of
transporter activity expressed in adherent cells. The efflux of anti-cancer
drug accumulates in the microchamber sealed by the intact cells for
detection by imaging.
the constructed microchamber device in measuring the transport
activity of anti-cancer drugs.
MATERIALS AND METHODS
REAGENT
NaCl, KCl, CaCl2, MgCl2, NaOH, and dimethysulfoxide (DMSO)
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 4-
(2-hydroxyethyl) piperazine-1-ethanesulfonicacid (HEPES) was
purchased from DOJINDO (Kumamoto, Japan). Glucose was
purchased from Wako Pure Chemicals Industries (Osaka, Japan).
CELL CULTURE
A human cervical carcinoma (HeLa) cell line was acquired from
the Japanese Cancer Research Resources Bank (JCRB). Cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma-Aldrich) supplemented with 10% fetal bovine serum
(FBS; Life Technologies Carlsbad, CA, USA) and 50 U/ml peni-
cillin/streptomycin (P/S; Sigma-Aldrich) at 37°C in 5% CO2.
For the microchamber experiment, cells cultured on dishes were
removed using a 0.25% trypsin-EDTA solution (Sigma-Aldrich)
and suspended in a basal salt solution (BSS) consisting of 130 mM
NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 5.5 mM glu-
cose, and 10 mM Hepes-NaOH (pH 7.3). The cell concentration
was adjusted to 3.0× 107 cell/ml for seeding on the microcham-
ber device. This cell concentration was optimized to achieve
confluency at about 90 min of incubation after seeding.
TRANSFECTION
HeLa cells were cultured on plastic Petri dishes containing media
without P/S for 24 h. Cells at 60–80% confluency were transfected
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with a plasmid expressing the ABC transporter protein MDR1
using lipofectamine LTX (Life Technologies). A plasmid vector
with green fluorescent protein (GFP)-tagged ORF clones of human
ABC, sub-family B, member 1 (MDR1/ABCB1) was purchased
from ORIGENE (Rockville, MD, USA). Cells were supplemented
with a solution containing plasmid DNA, a transfection reagent,
and Opti-MEM1 Reduced-Serum Medium (Life Technologies),
and were cultured for 24–48 h.
FABRICATION AND PREPARATION OF THE MICROCHAMBER DEVICE
A microchamber device made of poly-di-methyl siloxane (PDMS)
was fabricated by the standard soft-lithography process. First, pil-
lar structures, 15µm in diameter with a height of 30µm and
spacing of 15µm, were fabricated by a SU-8 negative photore-
sist (MicroChem Corp., Newton, MA, USA) on a 2′′ mirror-
polished silicon wafer (Ferrotec Silicon, Tokyo, Japan) according
to the manufacturer’s protocol. The scanning electron microscope
(SEM) image in Figure 2A was obtained using the 3D Real-surface
view (VE-8800; KEYENCE, Osaka, Japan). PDMS prepolymer
(Silpot 184; Corning Toray Co., Tokyo, Japan) mixed with a curing
reagent was poured onto the mold, degassed, and cured at ~70°C
for ~2 h. Then, the cured PDMS slab was peeled from the mold
(Figure 2B). Within a single microchamber device, with a dimen-
sion of 2 cm×2 cm, 2,160 chambers were arrayed, consisting of 4
subarrays of 9×60 chambers each. Each subarray was numbered
for ease of spotting specific locations. To retain the buffer and drug
solutions, a ring structure made of PDMS with an inner diameter
of 10 mm was placed on the microchamber device (Figure 2C).
The surface of the microchamber device was coated with
an extracellular matrix to enhance cell adhesion. Specifically,
the device was incubated with a solution of 50µg/ml human
fibronectin (BD Biosciences, San Jose, CA, USA) for 30 min at
room temperature. After washing with distilled–deionized water
(DDW), the device was stored at 4°C. Prior to use, the chamber
device was degassed for 10 min in a vacuum desiccator to avoid
bubbles becoming trapped in the microchambers.
CELL STAINING
To confirm cell adherence, imaging of cells with stained cellu-
lar membranes and nuclei was performed. HeLa cells attached
to the microchamber device were incubated with 0.5µg/ml
Hoechst33342 (Life Technologies) and 10µg/ml 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI; Life
Technologies) at 37°C for 20 min to stain the cell nucleus
and cell membrane, respectively. After washing with BSS, cells
were observed for fluorescence using a confocal laser scanning
microscope.
MICROSCOPIC OBSERVATION
Cells with GFP and fluorescent markers that had adhered to
the microchamber device were imaged using an inverted epi-
fluorescence microscope (IX 51; Olympus, Tokyo, Japan) or a
confocal laser scanning microscope (LSM-70; Carl Zeiss, Jena, Ger-
many). Acquired fluorescent images were subjected to fluorescence
intensity analysis using the ImageJ software. Statistical analyses
were performed with GraphPad Prism software (GraphPad, San
Diego, CA, USA) using the Student’s t -test.
EXPERIMENTAL DESIGN AND PROCEDURE
The measurement procedure for the drug transport assay in the
designed microchamber device is depicted in Figure 3. First, cells
that were detached with trypsin were seeded onto the microcham-
ber. Cells precipitated on the surface of the microchamber device,
and stayed at the surface instead of sinking into chambers since
their diameters were smaller than the typical diameter of a cell
(Figure 3, Step 1). The buffer used was supplemented with fluo-
rescently labeled dextran. When the chamber device was incubated
at 37°C for 90 min, cells spread to adhere and cover the chamber
(Figure 3, Step 2). After washing with buffer, microchambers with
confined spaces created by the cells were screened by observing the
fluorescent dextran remaining in the chamber (Figure 3, Step 3).
Following this, the buffer was exchanged for a buffer containing a
fluorescently labeled anti-cancer drug, and the whole device was
again incubated for 10 min (Figure 3, Step 4). At this step, the
anti-cancer drug was incorporated and accumulated in the cells.
Finally, the device was washed with the buffer to remove excess
of the anti-cancer drug, and fluorescent imaging was performed
(Figure 3, Step 5). When fluorescently labeled drugs were exported
from the cells expressing transporters, as confirmed by the fluo-
rescence of GFP, they accumulated within the confined spaces and
fluorescence intensity increased in a time-dependent manner.
In the present system, three types of fluorescent substances
were used: GFP as an expression marker of MDR1, fluorescent
dextran as a marker to confirm the hermeticity of the chamber,
and fluorescently labeled anti-cancer drugs. For imaging GFP, blue
excitation was used, whereas for the anti-cancer drug, paclitaxel
FIGURE 2 | Fabrication process of the microchamber device. (A) SEM image of the SU-8 master mold formed on a silicon wafer. (B) PDMS microchamber
device removed from the mold. (C) Microchamber device with the ring structure used to retain the buffer and reagents. This setup is mounted on the
microscope stage for imaging.
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FIGURE 3 | Experimental procedure. (1) Suspended cells in dextran
solution are seeded on the microchamber device. (2) Cells adhere to form a
confluent layer over the microchambers. (3) Buffer above the cells is
washed and the sealing of chambers was confirmed by fluorescent
imaging. (4) Drug is introduced, and incorporated into cells during
incubation. (5) After the second washing, the drug transported into
microchambers is measured by fluorescent imaging.
conjugated with BODIPY 564/570 (0.5µM in concentration; Life
Technologies), green excitation was used. To distinguish from
these two fluorescent substances, cascade blue-conjugated fluo-
rescent dextran (MW 3,000 or 10,000, 4µM in concentration; Life
Technologies), which can be observed under UV excitation, was
chosen. With this strategy, analysis of transport activity was con-
ducted on chambers covered by GFP-expressing cells and filled
with dextran.
To confirm if the measured increase in fluorescence was the
result of transporter activity and not from passive diffusion or
other unknown reasons, we conducted the experiment with an
inhibitor. In this case, 100µM of verapamil (Sigma-Aldrich), an
inhibitor of the MDR1 transporter, was added to all buffer solu-
tions used in the assay, i.e., the cell suspension in Step 1, buffer with
paclitaxel introduced in Step 4, and BSS used in Steps 3 and 5.
RESULTS
CELL MORPHOLOGY IN THE MICROCHAMBER DEVICE
We observed the adherence state and morphology of HeLa cells
seeded in the microchamber device. From a 3.0× 107 cell/ml sus-
pension of cells that were detached from the culture dish with
trypsin, 500µl was taken and used to seed cells in the device.
Suspended cells were spherical with a diameter of 15–20µm.
Thus, when they precipitated and reached the upper surface of the
chamber device, they did not fall inside the microchambers with
openings of 15µm in diameter (Figure 4A). The differential inter-
ference images taken after 90 min of incubation are shown in the
left image of Figure 4B. Cells are shown to have spread and adhered
over the device with 100% confluency. The morphology of cells
adhered to the flat PDMS surface was identical to that on the plas-
tic dish. As the morphology of cells overlapping with the chamber
was difficult to observe under bright-field imaging, we conducted
fluorescence imaging by staining cells. The overlaid image of nuclei
stained with Hoechst33342 and cell membranes stained with DiI
is shown in the right image of Figure 4B. The presence of hollows
had minimal effect on the morphologies of both membranes and
nuclei, and cells spread almost uniformly over the upper surface of
the PDMS device. To further examine whether cells had penetrated
into the microchambers, we compared microscopic images focus-
ing on either DiI-stained cells on the device surface or the interior
of chambers (10µm below the cell surface) (Figure 4C). No mem-
brane fluorescence was observed within most of the chambers,
suggesting these microchamber spaces remained vacant. Further,
no penetration was observed when the microchambers were com-
pletely covered with single cells. In some chambers, membrane
fluorescence was observed, and in such cases, the edge of a cell
overlapped with the opening of the microchamber. It is likely that
the periphery of cells penetrated into the microchamber along
the sidewall. Based on these results, HeLa cells seeded on this
microchamber device were confirmed to spread consistently, to
adhere, and to cover the microchamber.
CONFIRMATION OF THE SEALING PERFORMANCE OF THE
MICROCHAMBER COVERED BY CELLS
In this device, small, confined spaces are created by attaching
adherent cells over the openings of the microchambers, and
exported drugs accumulate within these spaces. Thus, good sealing
is required, so that drugs accumulated within the microchambers
do not leak out. The sealing performance was tested using two
types of fluorescent dextrans with MW of 3,000 and 10,000. After
detaching cells from a culture dish, 4µM of fluorescent dextran
was added to the cell suspension. When cells reached conflu-
ency, the microchamber layer (i.e., the layer 10µm below the cell
layer) was observed before the washing step (Figure 3, Step 2). At
this stage, fluorescence of both dextrans, with MW of 3,000 and
10,000, were uniform in all the microchambers (Figures 5A,C,
inset). Later, when the buffer was exchanged at the washing step
(Figure 3, Step 3), fluorescence disappeared in the majority of
the microchambers, but residual fluorescence was still observed
in some of the chambers (Figures 5B,D, inset). A histogram in
Figure 5 demonstrates the distribution of fluorescent intensity
derived from all 540 chambers in a single experiment. In the exper-
iment with MW 3,000 dextran, two distinct peaks were clearly
observed after washing (Figure 5B), indicating the microcham-
bers at the higher intensity peak were closed. The fraction of
microchambers with a fluorescent intensity of 40 or above, the
value at the valley of the peaks was 18.2%. In the case of MW
10,000 dextran, a similar fraction of microchambers was closed.
Microchambers with an intensity above 40 were 20.2% of the total
number of chambers (Figure 5D). That is, ~20% of the cham-
bers had achieved a sealing performance high enough so that the
fluorescent dextran would not be washed away.
Next, temporal changes in fluorescent intensity within the
microchambers after washing were observed. Images were taken
every 5 min, and time-course data for representative microcham-
bers are shown in Figure 6. In the case of fluorescent dextran with
a MW of 3,000, in most of the microchambers that retained flu-
orescent dextran after the buffer wash, the fluorescent intensity
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FIGURE 4 | (A) HeLa cells right seeding on the microchamber device. (Left)
differential interference contrast (DIC) image, (center) fluorescence image of
the plasma membrane, (right) overlaid image. (B) HeLa cells spread over the
microchamber device after incubation. (Left) DIC image, (right) fluorescence
image. The red color shows the plasma membrane stained by DiI and the blue
color shows the nucleus stained by Hoechst33342. (C) Imaging of the plasma
membrane obtained at the surface of the chamber device (0µm, left) and at
the middle of the chamber (−10µm, right).
tended to decrease in a time-dependent manner to ~30% of the
starting intensity within 40 min after the wash. In contrast, no
time-dependent change was observed in microchambers in which
no fluorescence was observed immediately after the buffer wash
(Figure 6A). In the case of fluorescent dextran with a MW of
10,000, three patterns of changes in intra-chamber fluorescent
intensity were observed (Figure 6B). In microchambers with high
fluorescent intensity immediately after the wash, the decrease
in fluorescent intensity was only about 10% at t = 60 min. In
microchambers with intermediate fluorescent intensity imme-
diately after the wash, the fluorescent intensity decreased to
about 50% within 30 min of the wash, in comparison with the
intensity observed immediately after washing. In microchambers
with almost no fluorescence immediately after the wash, almost
no time-dependent change was observed. The proportions of
microchambers demonstrating each of these three patterns were
5, 15, and 80%, respectively.
TRANSPORTER ACTIVITY ASSAY
Finally, we conducted the transporter activity assay with HeLa
cells over-expressing the ABC transporter MDR1. After achieving
confluency on the microchamber device, a buffer containing
fluorescent dextran was exchanged with BSS. At this stage, images
of fluorescent dextran and GFP were obtained. From these
images, we located the microchambers where cells expressing
GFP fused to MDR1 were covering chambers to form a con-
fined space for later analysis (Figure 7A). Next, the buffer with
0.5µM paclitaxel, an anti-cancer drug, conjugated with BOD-
IPY 564/570 was introduced. After incubation for 10 min the
excess drug was washed out. The cellular uptake of fluorescent
paclitaxel, due to passive transport across the plasma membrane,
was confirmed by the observation of intense red fluorescence
in cells (Figure 7B). Following this, time-lapsed images were
obtained. Since paclitaxel is known to bind to tubulin (Jordan
et al., 1996; Jordan and Wilson, 1998) and microtubules, flu-
orescent paclitaxel remained in cells without MDR1 for more
than an hour, which was consistent with previous literature
(Jang et al., 2001). However, in the microchambers covered by
MDR1-expressing cells and with enclosed fluorescent dextran, a
time-dependent increase in fluorescence intensity was observed
(Figure 7C red line). Conversely, in microchambers covered
by cells without MDR1 but with fluorescent dextran enclosed,
no increase in fluorescence intensity was observed (Figure 7C
blue line). Note that statistically significant differences were
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FIGURE 5 | Distribution of the intensity from fluorescent dextran retained in microchambers. (A) MW 3,000, before washing. (B) MW 3,000, after
washing. (C) MW 10,000, before washing. (D) MW 10,000, after washing. All scale bars in micrographs represent 50µm.
FIGURE 6 |Time-course of the fluorescence intensity retained in the
selected microchamber. Data points obtained at every 5 min were plotted
for clarity. (A) MW 3,000. (B) MW 10,000. All scale bars in micrographs
represent 50µm.
observed at 30, 40, and 50 min after starting the measurement.
We also conducted the experiment in the presence of the MDR1
inhibitor, verapamil. In this case, no obvious differences were
observed in the cell morphology and expression of MDR1
(Figures 8A,B). However, no significant differences were observed
within microchambers with cells either expressing or not express-
ing MDR1 and with dextran enclosed in both (Figure 8C). The
fluorescence intensity with paclitaxel in every chamber remained
unchanged.
Based on these results, the transporter-dependent accumula-
tion of paclitaxel within the confined spaces of microchambers
was confirmed. Furthermore, it is worth mentioning that, as the
size of chamber openings was smaller than the size of cells, the
observed concentration increase represents the increase from a
single cell.
DISCUSSION
In this study, we aimed to develop a microchamber device for
directly detecting drug transport via transporters of adherent cells.
We examined the extent of the formation of confined spaces by
coverage with adherent cells seeded on the microchambers. Fur-
thermore, by using cells over-expressing the transporter protein,
we successfully detected the transport activity of fluorescently
labeled anti-cancer drugs at the single-cell level.
We used HeLa cells as our model cell line and found that these
cells spread to confluence over the microchambers with diameters
of 15µm, without falling or penetrating into the microchambers.
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FIGURE 7 | Drug transport assay. (A) Bright and fluorescence images,
showing the cell morphology, MDR1 expressed in the cell, and fluorescent
dextran retained in the microchamber, respectively. Microchambers
enclosed by the MDR1-expressing cell can be spotted in the merged
image. (B) Fluorescent image showing paclitaxel incorporated into the
cell after incubation. (C) Time-course of fluorescence intensity in the
microchambers covered by MDR1 positive cells (red line) and MDR1
negative cells (blue line), both retaining dextran. Each line represents the
average of five independent chambers indicated by the arrows with
corresponding colors in the merged image. Data are presented as the
mean±SEM. *P <0.05 by Student’s t -test. All scale bars in micrographs
represent 50µm.
FIGURE 8 | Drug transport assay with the inhibitor. (A) Bright and
fluorescence images, showing the cell morphology, MDR1 expressed in the
cell, and fluorescent dextran retained in the microchamber, respectively.
Microchambers enclosed by the MDR1-expressing cell can be spotted in the
merged image. (B) Fluorescent image showing paclitaxel incorporated into
the cell after incubation. (C) Time-course of fluorescence intensity in the
microchamber for MDR1 positive (red line) cells and MDR1 negative cells
(blue line) both retaining dextran. Each line represents the average of four
independent chambers indicated by the arrows with corresponding colors in
the merged image. Data are presented as the mean±SEM and significance
was assessed using the Student’s t -test. All scale bars in micrographs
represent 50µm.
As a result, ~20% of the chambers were in a closed state so that
the contents would not be washed away when rinsed with a buffer.
However, the sealing performance was not high enough to retain
molecules with a MW of 3,000 (~1.6 nm in gyration radius) (Fish-
man et al., 1987). For molecules with a MW of 10,000 (~2.9 nm in
gyration radius), complete sealing was achieved in about 5% of the
chambers within the assay period. In general, cells attached to the
extracellular matrix at points called focal adhesions (FAs) (Geiger
et al., 2001; Berrier and Yamada, 2007), so that the presence of
shallow spaces in between was expected. As HeLa cells do not form
tight junctions, which are seen between epithelial cells, it is likely
that they cannot achieve the sealing performance to completely
prevent nanometric molecules from diffusing out. The ability to
form a hermetic seal is expected to depend on the cell type and
size of chamber openings, both areas that we will continue to
investigate.
www.frontiersin.org March 2015 | Volume 3 | Article 32 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tsugane et al. Microchamber for transporter activity detection
The MW of the substrate (fluorescent paclitaxel) used in this
study for the transport assay of an anti-cancer drug was 1,099.
Therefore, in this work, the drug transported into a microcham-
ber should not be completely retained and likely diffused out at
a certain rate. Nevertheless, a significant increase in fluorescent
intensity was observed in association with paclitaxel transport into
the chambers enclosed by MDR1-expressing cells. This was likely
due to the accumulation of the drug when transport exceeded
leakage by passive diffusion through the gap between cells and the
device wall, although further investigation is needed to verify this
hypothesis.
This work provides the first step toward the rapid, easy detec-
tion of transporter activity at the single-cell level, by directly
using intact adherent cells to form closed microchambers. The
fact that the accumulation of fluorescent substrate transported
into a microchamber was measurable using a standard cell line
(e.g., HeLa cell) suggests that our strategy is likely to be applicable
to other adherent cells, including cells from clinical samples. The
device used in this study was different from the transwell device
described in the introduction. Our device does not require com-
plete confluence of cells and can be used even in a case where the
distribution of cells is patchy. Therefore, an assay can be conducted
with trace amounts of samples. Furthermore, as the detected trans-
porter activity is intrinsically from a single cell, this assay may be
applicable to investigating cellular diversity in cancer tissues or to
detecting rare cells in a population in future studies. To facilitate
these applications, the sealing property of microchambers should
be well characterized for various cell types, culture conditions, and
sizes of microchamber openings. We will continue investigating
this issue to increase the scope of applications for this device.
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